These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21468258)

  • 1. VEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinoma.
    Yoon MS; Nam TK; Lee JS; Cho SH; Song JY; Ahn SJ; Chung IJ; Jeong JU; Chung WK; Nah BS
    J Korean Med Sci; 2011 Apr; 26(4):513-20. PubMed ID: 21468258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
    Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
    Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
    Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
    Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
    Hsieh HY; Hsu CP; Yeh HL; Chuang CY; Lin JF; Chang CF
    Kaohsiung J Med Sci; 2018 May; 34(5):281-289. PubMed ID: 29699635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
    Tamura T; Kuwahara A; Yamamori M; Nishiguchi K; Nakamura T; Okuno T; Miki I; Manabe Y; Sakaeda T
    Int J Med Sci; 2012; 9(10):833-7. PubMed ID: 23155356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in Chinese patients with esophageal squamous cell carcinoma.
    Cui Y; Dong C; Wu BQ; Duan XC; Shi G; Gong M; Wang TY
    J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C44-8. PubMed ID: 26323923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.
    Chen YH; Lu HI; Lo CM; Wang YM; Chou SY; Hsiao CC; Huang CC; Shih LH; Chen SW; Li SH
    BMC Cancer; 2018 Aug; 18(1):837. PubMed ID: 30126380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclooxygenase-2 expression after preoperative chemoradiotherapy correlates with more frequent esophageal cancer recurrence.
    Yoshikawa R; Fujiwara Y; Koishi K; Kojima S; Matsumoto T; Yanagi H; Yamamura T; Hashimoto-Tamaoki T; Nishigami T; Tsujimura T
    World J Gastroenterol; 2007 Apr; 13(16):2283-8. PubMed ID: 17511025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of concurrent chemoradiotherapy on serum vascular endothelial growth factor in esophageal squamous cell carcinoma patients--a report of 43 cases].
    Wang XS; Liu MZ; Zhang CQ; Cai L; Cui NJ
    Ai Zheng; 2006 Nov; 25(11):1428-32. PubMed ID: 17094915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between radiation dose and pathological complete response after preoperative radiochemotherapy in esophageal squamous cell cancer.
    Ordu AD; Nieder C; Geinitz H; Scherer V; Kup PG; Schuster T; Combs SE; Fakhrian K
    Anticancer Res; 2014 Dec; 34(12):7255-61. PubMed ID: 25503157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma.
    Zhao C; Lin L; Liu J; Liu R; Chen Y; Ge F; Jia R; Jin Y; Wang Y; Xu J
    Oncotarget; 2016 Aug; 7(35):57310-57316. PubMed ID: 28087951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy.
    Gaffney DK; Haslam D; Tsodikov A; Hammond E; Seaman J; Holden J; Lee RJ; Zempolich K; Dodson M
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):922-8. PubMed ID: 12829126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
    Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N
    Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience.
    Wang S; Liao Z; Chen Y; Chang JY; Jeter M; Guerrero T; Ajani J; Phan A; Swisher S; Allen P; Cox JD; Komaki R
    J Thorac Oncol; 2006 Mar; 1(3):252-9. PubMed ID: 17409865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Clinical Results of Concurrent Chemoradiotherapy for Patients with Cervical Esophageal Squamous Cell Carcinoma.
    Kumabe A; Zenda S; Motegi A; Onozawa M; Nakamura N; Kojima T; Daiko H; Shigematsu N; Akimoto T
    Anticancer Res; 2017 Sep; 37(9):5039-5044. PubMed ID: 28870931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy.
    Hickey K; Grehan D; Reid IM; O'Briain S; Walsh TN; Hennessy TP
    Cancer; 1994 Sep; 74(6):1693-8. PubMed ID: 7915963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma.
    Lin WC; Ding YF; Hsu HL; Chang JH; Yuan KS; Wu ATH; Chow JM; Chang CL; Chen SU; Wu SY
    Cancer; 2017 Oct; 123(20):3904-3915. PubMed ID: 28608916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
    Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
    Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor is a possible predictor of sensitivity to chemoradiotherapy in the primary lesion of esophageal squamous cell carcinoma.
    Gotoh M; Takiuchi H; Kawabe S; Ohta S; Kii T; Kuwakado S; Katsu K
    Jpn J Clin Oncol; 2007 Sep; 37(9):652-7. PubMed ID: 17940077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes from chemoradiotherapy for patients with esophageal cancer.
    Pantling AZ; Gossage JA; Mamidanna R; Newman G; Robinson A; Manifold DK; Hale PC
    Dis Esophagus; 2011 Apr; 24(3):172-6. PubMed ID: 21073614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.